Intech Investment Management LLC bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,941 shares of the company's stock, valued at approximately $983,000.
Other hedge funds have also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. purchased a new position in Axsome Therapeutics in the 2nd quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Axsome Therapeutics during the 2nd quarter valued at $47,000. Russell Investments Group Ltd. grew its holdings in Axsome Therapeutics by 5,550.0% during the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company's stock valued at $63,000 after buying an additional 777 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock valued at $156,000 after buying an additional 318 shares during the last quarter. Finally, Moors & Cabot Inc. acquired a new stake in Axsome Therapeutics during the 3rd quarter valued at $200,000. 81.49% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. Robert W. Baird increased their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Needham & Company LLC reiterated a "buy" rating and set a $130.00 target price on shares of Axsome Therapeutics in a report on Tuesday, November 12th. StockNews.com upgraded Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. UBS Group lowered their target price on Axsome Therapeutics from $107.00 to $105.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Finally, Wells Fargo & Company started coverage on Axsome Therapeutics in a report on Tuesday, September 3rd. They set an "overweight" rating and a $140.00 price objective on the stock. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $124.93.
Get Our Latest Research Report on AXSM
Insider Buying and Selling
In related news, Director Mark E. Saad sold 11,016 shares of the business's stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the transaction, the director now owns 10,002 shares in the company, valued at approximately $913,282.62. The trade was a 52.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 22.40% of the company's stock.
Axsome Therapeutics Stock Up 2.7 %
Shares of AXSM traded up $2.62 during midday trading on Thursday, reaching $99.65. 487,421 shares of the company were exchanged, compared to its average volume of 619,294. The stock has a 50-day moving average price of $91.37 and a 200-day moving average price of $85.57. The company has a market cap of $4.83 billion, a price-to-earnings ratio of -15.26 and a beta of 1.26. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $105.00. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The company had revenue of $104.76 million for the quarter, compared to analysts' expectations of $98.71 million. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. Research analysts expect that Axsome Therapeutics, Inc. will post -4.75 earnings per share for the current year.
Axsome Therapeutics Profile
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Featured Articles
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
